Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MBOAT4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | MBOAT4 Lentivirus Premade Particles Full-length human ORF (codon-optimized), CMV promoter, Puromycin selection, HEK293 packaged. Titer >1x10^8 TU/mL. Also available as Promise-ORF/Lentivirus for stable cell line generation. |
View MBOAT4 Products |
| Membrane Assay System | MBOAT4 Stable Cell Line Lysate HEK293 cells stably expressing human MBOAT4, membrane fraction purified, Endotoxin <1EU/mg. Sequence Verified. |
View MBOAT4 Products |
| Benchmark Ab | Anti-MBOAT4 Recombinant Positive Control Antibody (Clone 4C11) Mouse monoclonal IgG, C-terminal epitope, validated for Western and IP. High Purity (>95%). |
View MBOAT4 Products |
| Validator | MBOAT4 siRNA Set (3 unique targets) For knockdown verification and specificity controls. HPLC purified. |
View MBOAT4 Products |
| Substrate Control | Ghrelin (Active Form) Human ghrelin (1-28), Octanoylated, Synthetic. High Purity (>95%). For enzymatic assays. |
View Ghrelin Products |
| Pathway Partner | GHSR (Growth Hormone Secretagogue Receptor) Full-length lentivirus for functional signaling assays (calcium flux). |
View GHSR Products |
| Selectivity Control | MBOAT2 (Lysophospholipid Acyltransferase) Recombinant membrane preparation for counter-screening off-target effects. |
View MBOAT2 Products |
Critical Assay Challenge vs TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane topology preservation for enzymatic activity | Lentivirus-transduced HEK293 cells expressing native conformation MBOAT4 with correct membrane insertion verified by flow cytometry |
| Substrate (Ghrelin) co-expression for octanoylation assays | Dual-promoter lentivirus or co-transfection system available with Ghrelin ORF (View Ghrelin Products) |
| MBOAT family selectivity screening (MBOAT1/2/7) | Ortholog and paralog membrane protein panel (Human/Mouse/Cyno) with sequence identity verified by mass spec |
| Catalytic dead controls for assay validation | Site-directed mutant lentivirus available (H338A catalytic dead), Sequence Verified |
| Cross-species translation (rodent to primate) | Human, Mouse, Rat, and Cynomolgus MBOAT4 lentivirus with conserved active site alignment |
| Lack of Controls / False Positives | Recombinant positive control antibodies and validated siRNA included for specificity checks. |
Live MBOAT4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MBOAT4/GOAT therapeutics is intensifying. As a critical enzyme activating ghrelin, inhibiting MBOAT4 presents a promising pathway for treating obesity, diabetes, and Prader-Willi syndrome. Major players are shifting focus from traditional enzyme kinetics to cell-based inhibitor screening and brain-penetrant small molecules. First-generation peripheral inhibitors show promise, while next-wave R&D targets central nervous system penetration for appetite control and oncology applications where ghrelin signaling promotes tumor proliferation. Future trends point towards combining MBOAT4 inhibitors with GLP-1 agonists to maximize weight loss and metabolic control.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic consortia, Early-stage Biotech | Obesity, Type 2 Diabetes | Membrane-based Enzymatic Assay (Need intact MBOAT4 expressing cells) |
| Peptide Inhibitor (e.g., GO-CoA-Tat) | Research Institutions | Metabolic Syndrome | Cell Permeability & Internalization Assay |
| Antisense Oligonucleotide | Specialized Genetic Medicine Firms | NAFLD/NASH | Gene Knockdown Validation (Need siRNA controls) |
| Dual Ghrelin/GHSR Modulators | Metabolic Disease Focused Biotechs | Cancer Cachexia | Pathway Integration Assay (MBOAT4 + GHSR co-expression) |
Key Genetic Variants
Key mutations in MBOAT4 (UniProt Q96T53):
- rs7813902: Does not affect octanoyltransferase activity (evidence: UniProt VAR_059434).
- rs16876563: Documented variant (evidence: UniProt VAR_030069). These variants are useful for designing negative controls and assessing drug resistance profiles.